174 related articles for article (PubMed ID: 6191673)
21. MX2, a morpholino anthracycline, as a new antitumor agent against drug-sensitive and multidrug-resistant human and murine tumor cells.
Watanabe M; Komeshima N; Nakajima S; Tsuruo T
Cancer Res; 1988 Dec; 48(23):6653-7. PubMed ID: 3180075
[TBL] [Abstract][Full Text] [Related]
22. DNA strand scission in vivo and in vitro by auromomycin.
Suzuki H; Nishimura T; Tanaka N
Cancer Res; 1979 Jul; 39(7 Pt 1):2787-91. PubMed ID: 445483
[TBL] [Abstract][Full Text] [Related]
23. Studies on antineoplastic activity of naphthomycin, a naphthalenic ansamycin, and its mode of action.
Okabe T; Yuan BD; Isono F; Sato I; Fukazawa H; Nishimura T; Tanaka N
J Antibiot (Tokyo); 1985 Feb; 38(2):230-5. PubMed ID: 3997667
[TBL] [Abstract][Full Text] [Related]
24. Antitumor activity of siwenmycin: a novel anthracycline antibiotic.
Shen W; Chen R; Zhou M; Chen Y; Hu Q; Wang H; Wang Y; Jiao H
Pharmacology; 1992; 45(4):181-7. PubMed ID: 1438526
[TBL] [Abstract][Full Text] [Related]
25. In vivo antitumor activity of S 16020-2, a new olivacine derivative.
Guilbaud N; Kraus-Berthier L; Saint-Dizier D; Rouillon MH; Jan M; Burbridge M; Visalli M; Bisagni E; Pierré A; Atassi G
Cancer Chemother Pharmacol; 1996; 38(6):513-21. PubMed ID: 8823492
[TBL] [Abstract][Full Text] [Related]
26. Antitumor activity and hematotoxicity of a new, substituted dihydrobenzoxazine, FK973, in mice.
Shimomura K; Manda T; Mukumoto S; Masuda K; Nakamura T; Mizota T; Matsumoto S; Nishigaki F; Oku T; Mori J
Cancer Res; 1988 Mar; 48(5):1166-72. PubMed ID: 3342397
[TBL] [Abstract][Full Text] [Related]
27. Alteration of plasma membrane of drug-resistant tumor cells: 230-kilodalton protein identified by monoclonal antibody.
Sugimoto Y; Suzuki H; Tanaka N
Biochem Biophys Res Commun; 1983 Aug; 114(3):969-75. PubMed ID: 6577861
[TBL] [Abstract][Full Text] [Related]
28. Antitumor activity of a new antitumor antibiotic, stubomycin.
Komiyama K; Edanami K; Yamamoto H; Umezawa I
J Antibiot (Tokyo); 1982 Jun; 35(6):703-6. PubMed ID: 7118726
[TBL] [Abstract][Full Text] [Related]
29. Aclarubicin inhibits etoposide induced apoptosis through inhibition of RNA synthesis in P388 murine leukemic cells.
Nagata T; Higashigawa M; Shimono Y; Cao DC; Yan Mao X; M'soka T; Inamochi H; Hori H; Kawasaki H; Sakurai M
J Exp Clin Cancer Res; 1998 Dec; 17(4):435-42. PubMed ID: 10089064
[TBL] [Abstract][Full Text] [Related]
30. Transplantability and sensitivity to natural killer cells of aclarubicin-resistant murine lymphoma.
Sugimoto Y; Hirakawa Y; Tanaka N; Tahara M; Sato I; Nishimura T; Suzuki H; Tanaka N
Cancer Res; 1986 Nov; 46(11):5646-8. PubMed ID: 3463416
[TBL] [Abstract][Full Text] [Related]
31. Antitumor efficacies of aclacinomycin A by oral administration.
Tsukagoshi S; Tsuruo T; Yamori T; Iida H; Naganuma K; Sakurai Y
J Pharmacobiodyn; 1980 Oct; 3(10):532-6. PubMed ID: 6937651
[TBL] [Abstract][Full Text] [Related]
32. [Antitumor activity of macromomycin].
Kato T; Yamanaka N; Katayama S; Mizutani M; Ota K
Gan To Kagaku Ryoho; 1982 Jul; 9(6):1097-101. PubMed ID: 7184442
[TBL] [Abstract][Full Text] [Related]
33. (R,R)-2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]- bis[5-nitro-1H-benz[de]isoquinoline-1,3-(2H)-dione] dimethanesulfonate (DMP 840), a novel bis-naphthalimide with potent nonselective tumoricidal activity in vitro.
Kirshenbaum MR; Chen SF; Behrens CH; Papp LM; Stafford MM; Sun JH; Behrens DL; Fredericks JR; Polkus ST; Sipple P
Cancer Res; 1994 Apr; 54(8):2199-206. PubMed ID: 8174127
[TBL] [Abstract][Full Text] [Related]
34. [New anthracycline antibiotics and derivatives].
Tatsuta K
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2640-52. PubMed ID: 6594977
[TBL] [Abstract][Full Text] [Related]
35. Azinomycins A and B, new antitumor antibiotics. III. Antitumor activity.
Ishizeki S; Ohtsuka M; Irinoda K; Kukita K; Nagaoka K; Nakashima T
J Antibiot (Tokyo); 1987 Jan; 40(1):60-5. PubMed ID: 3104267
[TBL] [Abstract][Full Text] [Related]
36. Potentiation of adriamycin accumulation and effectiveness in adriamycin-resistant cells by aclacinomycin A.
Tapiero H; Boulé D; Trincal G; Fourcade A; Lampidis TJ
Leuk Res; 1988; 12(5):411-8. PubMed ID: 3164087
[TBL] [Abstract][Full Text] [Related]
37. [Antitumor drugs and potentiators aiming circumvention of drug resistance].
Suzuki H
Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 1):335-41. PubMed ID: 1689986
[TBL] [Abstract][Full Text] [Related]
38. [Aclacinomycin A: a new antitumor antibiotic].
Egorov LV; Ivanitskaia LP; Navashin SM
Antibiotiki; 1982; 27(7):540-55. PubMed ID: 6753735
[No Abstract] [Full Text] [Related]
39. Interaction of aclarubicin with DNA as compared with daunorubicin and doxorubicin.
Ando S; Sasada M; Uchino H; Kagawa D; Ueda T; Nakamura T
Nihon Gan Chiryo Gakkai Shi; 1986 Dec; 21(10):2343-55. PubMed ID: 3471823
[No Abstract] [Full Text] [Related]
40. [Discovery and development of unknown potentialities of microorganisms with special reference to saframycin group antitumor antibiotics].
Arai T
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2617-24. PubMed ID: 6508318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
